Last 20 years, great progress has been made in the care of advanced non-small cell lung cancer,
especially adenocarcinoma. One year survival of advanced non-small cell lung cancer increases
from 30% to 55%. Third-generation regimens with or without front-line targeted agents, or with
efficient second- and third line low toxicity therapies may contribute improving survival. The
emergence of targeted therapy in first- and second-line settings has spectacularly changed the natural history of disease especially EGFR mutated cancer, leading to dramatically prolonged overall survival. Maintenance therapy, either with targeted agents or cytotoxic agents, also improved survival for larger groups of non-small cell lung cancer.